

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Boan Biotech
博安生物

Shandong Boan Biotechnology Co., Ltd.

山东博安生物技术股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6955)

VOLUNTARY ANNOUNCEMENT

AUTHORIZATION TO ZENCORE BIOLOGICS TO USE BA-HIEXCELL® STABLE CELL LINE DEVELOPMENT PLATFORM

The board of directors (the “**Board**”) of Shandong Boan Biotechnology Co., Ltd. (the “**Company**”) announces that the Company has entered into an agreement with the Zencore Biologics Co., Ltd. (“**Zencore Biologics**”), authorizing Zencore Biologics to use its self-developed stable cell line development platform, BA-HIEXcell® for the development of antibodies and therapeutic proteins.

BA-HIEXcell® is a proprietary platform of the Company for the development of stable cell lines. The key of this platform is a highly efficient expression vector that can increase the expression levels and stability of exogenous genes. In combination with a rapid cell line screening process, BA-HIEXcell® stable cell line platform can generate monoclonal cell lines for production within 10 weeks. The platform has been validated in different types of projects, showing that it is capable of rapidly generating multiple highly expressed and stable monoclonal cell lines while reducing screening workload. This is a cutting-edge platform in the industry in terms of both the efficiency and the expression levels in cell line development.

As a Contract Development and Manufacturing Organization (“**CDMO**”), Zencore Biologics provides comprehensive services from preclinical development to commercial production for biopharmaceutical clients around the world. The development of cell lines is crucial to the quality and process yield of macromolecular drugs, and also directly affects their development efficiency and manufacturing costs. BA-HIEXcell® stable cell line platform optimizes cell line development, and solves the pain points of long development cycles and heavy screening workload associated with traditional platforms. It can efficiently obtain high-yield, high-quality and stable monoclonal cell lines and can reduce development time to 8 months from DNA sequence to IND submission. The BA-HIEXcell® stable cell line platform will complement Zencore Biologics’ existing cell line platform, and will help Zencore Biologics accelerate the development of drug candidates and reduce the costs of the commercial production for its clients.

Currently, the Company operates across the entire value chain of the industry covering antibody discovery, cell line development, upstream and downstream process development, quality analysis, in vitro and in vivo bio-analysis method development, technology transfer, non-clinical research, clinical research, regulatory affairs and registration, and commercial production. The Company's portfolio includes two commercial products and multiple novel biologic candidates protected by international intellectual property rights, as well as a number of biosimilar candidates, thanks to its strong CMC (Chemical, Manufacturing and Control) and comprehensive R&D capabilities.

ABOUT ZENCORE BIOLOGICS

Zencore Biologics provides comprehensive CDMO services from preclinical development to commercial production for biopharmaceutical clients around the world. Specifically, its services include the CDMO of macromolecular biologics and antibody-drug conjugates (ADCs), the development and production of cell culture media and custom cell culture media, analysis and testing, quality control and registration, etc. It is committed to promoting and accelerating the development and commercialization of macromolecular drugs for pharmaceutical companies and research institutions around the world.

By Order of the Board
Shandong Boan Biotechnology Co., Ltd.
Jiang Hua

Chairlady, Chief Executive Officer and Executive Director

Yantai, the People's Republic of China, 30 January 2024

As at the date of this announcement, the executive directors of the Company are Ms. Jiang Hua and Dr. Dou Changlin; the non-executive directors of the Company are Mr. Liu Yuanchong and Ms. Li Li; and the independent non-executive directors of the Company are Mr. Shi Luwen, Mr. Dai Jixiong and Dr. Yu Jialin.